ACADIA Pharmaceuticals ACAD NASDAQ · Healthcare · United States
$17.83 -2.67% -$0.49
Summary
81 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 30 USD is left as net profit.
- Revenue grew by 27% a year over the last 3 years.
- It earns 19 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $322.4M against $71.9M.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 8.5 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 19% a year over 5 years. Over the last 3 years it grew by 27% a year. For the next fiscal year analysts expect revenue to grow by 19%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 9.5 USD
- Research and development 27 USD
- Sales and administration 54 USD
- Taxes and other -20 USD
- Net profit 30 USD
Net profit, industry median (Biotechnology) -10 USD
Out of every 100 USD of revenue, 30 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 25
- Hold 11
- Sell 1
Today's price within the analysts' price targets
The average target of $30.05 is 69% above today's price. 68% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2018By product
- Product 100%
By region
The company reports no revenue by region.
Product brings in 100% of revenue.
Segments in detail